AFP resumes rollout of China-made vaccines | Inquirer

AFP resumes rollout of China-made vaccines

By: - Reporter /
/ 08:49 PM June 14, 2021

MANILA, Philippines—The Armed Forces of the Philippines (AFP) on Monday (June 14) resumed its vaccination program using Coronavac, the vaccine brand manufactured by Chinese company Sinovac.

The vaccination program resumed after a “regular and steady” supply of the Chinese vaccines came in, said Capt. Jonathan Zata, AFP public affairs chief, in a statement.

The Camp General Emilio Aguinaldo Station Hospital received an initial 500 Coronavac doses for civilian and uniformed personnel assigned to Camp Aguinaldo, the AFP general headquarters.

Article continues after this advertisement

A regular supply of 20.5 million doses of Coronavac is seen until the end of October 2021, according to an advisory issued by the National Vaccination Operations Center on June 10, Zata said.

FEATURED STORIES

Additional doses were expected for military facilities in the National Capital Region.

The AFP has so far completed the delivery of 70,000 Coronavac doses to military treatment facilities nationwide last April 29.

Article continues after this advertisement

As of June 11, 34,390 AFP personnel have received two doses of Coronavac, while 34,978 have been given first dose shots.

Article continues after this advertisement

A total of 3,339 doses of AstraZeneca vaccines have also been distributed to military treatment facilities nationwide as of June 10.

TSB

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

TAGS: AFP, AstraZeneca, Coronavac, Sinovac

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2025 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.